Started in 2008, the Human Papillomavirus (HPV) Vaccine Impact Monitoring Project (HPV-IMPACT) monitors rates of high-grade cervical lesions in women in the United States. Scientists use data from the project to determine the impact of the U.S. HPV vaccination program on cervical precancers caused by HPV. High-grade cervical lesions are precancers that could progress to invasive cervical cancer if left untreated.
Since its inception in 2008, HPV-IMPACT has enabled CDC to describe trends in the cervical lesions that could progress to cancer and the reduction of vaccine-preventable cancer-causing HPV types (such as HPV16 and HPV18) in women diagnosed with these cervical lesions.
- Compared to 2008-2009, cervical precancer ratesexternal icon among screened females in 2014-2015 were 50% lower in 18- to 20-year-olds and 36% lower in 21- to 24-year-olds.
- The percentage of cervical lesions due to types that are prevented by the HPV vaccineexternal icon has dropped by 40% in vaccinated women since the vaccine was introduced.
- HPV-IMPACT data were used for the first national estimate of CIN2+ cases. We estimated that 196,000 CIN2+ cases were diagnosed in U.S. women in 2016, 36% of which were in women aged 18-29 years.